Didanosine
Links shared publicly online about this topic
Didanosine (Videx, ddI) - The Body
thebody.com — “ddI (Videx) is a drug used as part of antiretroviral therapy (ART). It is manufactured by Bristol-Myers Squibb and by Barr Laboratories. Didanosine is ...” View full resource at thebody.com
Most Recently Shared on February 9, 2010 at 1:01 pm By:
Newly Updated Fact Sheet: Didanosine (Videx, ddI) http://is.gd/7HBEa #hiv #didanosine #ddi #videx
VIDEX PEDIATRIC PWD for ORAL SOLN (Didanosine) drug information from MPR
empr.com — “VIDEX PEDIATRIC PWD for ORAL SOLN (Didanosine) drug information for HIV~antivirals from MPR including side effects, drug interactions, dosing, contraindications and precautions.” View full resource at empr.com
Most Recently Shared on March 19, 2010 at 4:47 am By:
MPR News: VIDEX PEDIATRIC PWD for ORAL SOLN: Precautions: added info on non-cirrhotic portal hypertension. http://bit.ly/97F6kf
VIDEX PEDIATRIC PWD for ORAL SOLN (Didanosine) drug information from MPR
empr.com — “VIDEX PEDIATRIC PWD for ORAL SOLN (Didanosine) drug information for HIV~antivirals from MPR including side effects, drug interactions, dosing, contraindications and precautions.” View full resource at empr.com
Most Recently Shared on June 18, 2009 at 6:29 am By:
MPR News: VIDEX PEDIATRIC PWD for ORAL SOLN: Dosing updated. http://tinyurl.com/mmmk3h
FDA Drug Safety Communication: Serious liver disorder associated with the use of Videx/Videx EC (didanosine)
fda.gov — “[01-29-2010] the u.s. food and drug administration (fda) is alerting healthcare professionals and patients about a rare, but serious, complication in the liver known as non-cirrhotic portal hypertension in patients using videx or videx ec (didanosine).” View full resource at fda.gov
Most Recently Shared on January 29, 2010 at 6:10 pm By:
RT @FDA_Drug_Info: FDA alert to rare, serious complication in pts using Videx / Videx EC (didanosine). http://bit.ly/Videx
FDA Alert: Videx/Videx EC (didanosine): Labeling Revision - Risk of Non-Cirrhotic Portal Hypertension
drugs.com — “FDA Alert: Videx/Videx EC (didanosine): Labeling Revision - Risk of Non-Cirrhotic Portal Hypertension” View full resource at drugs.com
Most Recently Shared on January 31, 2010 at 1:57 am By:
FDA Alert - FDA Warns of Non-Cirrhotic Portal Hypertension Risk in Patients Using Videx/Videx EC (didanosine) - http://bit.ly/cNElgB
Matrix Laboratories' ANDA for Didanosine Delayed-release Capsules receives FDA approval under PEPFAR
news-medical.net — “Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Didanosine Delayed-release Capsules, 125 mg, 200 mg, 250 mg and 400 mg, the generic version of Bristol Myers Squibb's HIV treatment Videx® EC.” View full resource at news-medical.net
Most Recently Shared on April 19, 2010 at 1:35 pm By:
Matrix Laboratories' ANDA for Didanosine Delayed-release Capsules receives FDA approval under PEPFAR: Mylan Inc. t... http://bit.ly/cxh5Cs
Bifunctional Peptidomimetic Prodrugs of Didanosine for Improved Intestinal Permeability and Enhanced Acidic Stability: Synthesis, Transepithelial Transport, Chemical Stability and Pharmacokinetics - Molecular Pharmaceutics (ACS Publications)
pubs.acs.org — “Bifunctional Peptidomimetic Prodrugs of Didanosine for Improved Intestinal Permeability and Enhanced Acidic Stability: Synthesis, Transepithelial Transport, Chemical Stability and Pharmacokinetics - Molecular Pharmaceutics (ACS Publications)” View full resource at pubs.acs.org
Most Recently Shared on March 6, 2011 at 3:13 am By:
Drugs and Devices OW OW Health
Bifunctional Peptidomimetic Prodrugs of Didanosine for Improved Intestinal Permeability and Enhanced Acidic Stab... http://bit.ly/f2ZU6J
Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal - Laurent - 2010 - Tropical Medicine & International Health - Wiley Online Library
onlinelibrary.wiley.com — “Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal - Laurent - 2010 - Tropical Medicine & International Health - Wiley Online Library” View full resource at onlinelibrary.wiley.com
Most Recently Shared on November 20, 2010 at 2:19 am By:
Longâ€*term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antir... http://bit.ly/bKG9Gn
Infectious Disease Article | Anti-Retroviral Agents
mdlinx.com — “Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal” View full resource at mdlinx.com
Most Recently Shared on December 3, 2010 at 6:57 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in ant... http://bit.ly/gBpkGK #ID
HIV drug causes liver damage, admits FDA
NaturalNews.com — “HIV drug causes liver damage, admits FDA” View full resource at NaturalNews.com
Most Recently Shared on July 19, 2010 at 5:34 am By:
HIV drug causes liver damage, admits FDA: (NaturalNews) The HIV drug Videx (sold generically as didanosine) may ca... http://bit.ly/dnzE7K
UNITAID: Drug factory closure could leave babies without HIV drugs
pediatricsupersite.com — “The planned closure of a Bristol-Myers Squibb drug factory this month in France could lead to massive shortages of didanosine, an essential seco” View full resource at pediatricsupersite.com
Most Recently Shared on June 11, 2010 at 5:20 pm By:
Pediatric SuperSite Health Site
#UNITAID: Drug factory closure could leave babies without #HIV drugs: http://ow.ly/1Xjgj
Videx and Videx EC labeling revised to include risk of non-cirrhotic portal hypertension - MPR
empr.com — “The FDA has notified healthcare professionals and patients that the use of Videx or Videx EC (didanosine, from Bristol-Myers Squibb) may cause non-cirrhotic portal hypertension, a rare but serious complication.” View full resource at empr.com
Most Recently Shared on January 29, 2010 at 10:01 pm By:
MPR News: Videx and Videx EC labeling revised to include risk of non-cirrhotic portal hypertension: The FDA has no... http://bit.ly/bRTWp9
Generic Videx EC approved for treatment of HIV - MPR
empr.com — “Mylan announced that the FDA has approved its Abbreviated New Drug Application (ANDA) for didanosine delayed-release capsules, the generic version of Videx EC (from Bristol Myers Squibb).” View full resource at empr.com
Most Recently Shared on April 19, 2010 at 5:16 pm By:
MPR News: Generic Videx EC approved for treatment of HIV: Mylan announced that the FDA has approved its Abbreviate... http://bit.ly/dbPfSl
Generic Videx EC approved for treatment of HIV - ONA
oncologynurseadvisor.com — “Mylan announced that the FDA has approved its Abbreviated New Drug Application (ANDA) for didanosine delayed-release capsules, the generic version of Videx EC (from Bristol Myers Squibb).” View full resource at oncologynurseadvisor.com
Most Recently Shared on April 19, 2010 at 4:30 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Generic Videx EC approved for treatment of HIV http://goo.gl/fb/vXjZ3
Old HIV drug found to produce rare liver problem, FDA says | Booster Shots | Los Angeles Times
latimesblogs.latimes.com — “Didanosine, the second drug approved for the treatment of HIV infections and one of the oldest weapons in the AIDS armamentarium, has been found to produce rare cases of potentially fatal liver disease in patients taking it for long periods,...” View full resource at latimesblogs.latimes.com
Most Recently Shared on February 1, 2010 at 7:20 pm By:
LA Times Health News Health News
Old HIV drug found to produce rare liver problem, FDA says http://bit.ly/deXWM7
The Top 3 resources shared on this topic. More resources.
Advertisement
